Mounjaro Kwikpen

Mounjaro is a medication that is approved to improve blood sugar control in adults with type 2 diabetes. Recently, Mounjaro received approval for weight loss in adults with obesity (BMI≥30) or overweight (BMI≥27) with a weight-related condition. Both Mounjaro and Zepbound (available in the US) have the same active ingredient, tirzepatide. Tirzepatide, including both Mounjaro (FDA-approved for treatment of type 2 diabetes) and Zepbound (FDA-approved for weight loss), is a glucagon-like peptide 1 (GLP-1) receptor agonist and a glucose-dependent insulinotropic polypeptide (GIP) agonist. This means that tirzepatide acts like the GLP-1 and GIP hormones to lower blood sugar levels and decrease your appetite so you lose weight. It also slows down how fast food moves through your body, which may help you stay full for longer. Both Mounjaro and Zepbound are once-weekly medications administered via a single-use prefilled injection pen with the prescribed dose. You administer the injection under the skin of your stomach, thigh, or arm. Tirzepatide comes in doses of 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg. Similar to other GLP-1 medications, tirzepatide dosing gradually increases. If prescribed, you’ll start on the lowest dose (2.5 mg) for the first four weeks, and then work with your provider to slowly increase your dose every four weeks until you reach a steady dose that works best for you